Skip to main content
. 2020 May 6;13:3823–3837. doi: 10.2147/OTT.S240721

Figure 5.

Figure 5

The combination of chidamide and bortezomib synergistically inhibited the invasive abilities of MGC-803 and BGC-823 cells. The MGC-803 and BGC-823 cell lines were treated with chidamide (30 µM for MGC-803 or 20 µM for BGC-823), bortezomib (15 nM), chidamide (120 µM for MGC-803 or 80 µM for BGC-823), or chidamide (30 µM for MGC-803 or 20 µM for BGC-823) in combination with bortezomib (15 nM) for 48 hours. (A and B) Representative images of the cell invasion assay results at 24 hours after the different treatments (magnification ×100). Invasive cells were quantified on the basis of the average of four randomly chosen high-power fields from the independent experiments performed in duplicate (One-way ANOVA with Bonferroni’s posthoc test was applied to compare the indicated groups. ***P<0.001, compared with the negative control, chidamide-, or bortezomib-alone groups). (C and D) Representative images of the expression of the invasion-related proteins N-cadherin, MMP2, and VEGF.